17.52
1.63%
-0.29
After Hours:
17.22
-0.30
-1.71%
Kura Oncology Inc stock is traded at $17.52, with a volume of 873.19K.
It is down -1.63% in the last 24 hours and down -2.88% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
See More
Previous Close:
$17.81
Open:
$18
24h Volume:
873.19K
Relative Volume:
1.63
Market Cap:
$1.33B
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-8.5463
EPS:
-2.05
Net Cash Flow:
$-138.01M
1W Performance:
+0.92%
1M Performance:
-2.88%
6M Performance:
-15.08%
1Y Performance:
+94.45%
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-22-23 | Initiated | Mizuho | Buy |
Aug-11-23 | Initiated | BofA Securities | Buy |
Jul-27-23 | Initiated | Scotiabank | Sector Perform |
May-17-23 | Initiated | BTIG Research | Buy |
Jan-31-23 | Initiated | Stifel | Buy |
Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
Feb-15-22 | Initiated | Jefferies | Buy |
May-05-21 | Resumed | Credit Suisse | Outperform |
Apr-26-21 | Resumed | Credit Suisse | Outperform |
Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
Dec-03-20 | Initiated | Stifel | Buy |
Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
Jul-07-20 | Initiated | Credit Suisse | Outperform |
May-05-20 | Initiated | Barclays | Overweight |
Jul-18-19 | Initiated | Deutsche Bank | Buy |
Nov-09-18 | Initiated | Piper Jaffray | Overweight |
Aug-01-18 | Initiated | H.C. Wainwright | Buy |
Oct-13-16 | Resumed | Leerink Partners | Outperform |
Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
Dec-30-15 | Initiated | Oppenheimer | Outperform |
Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
When the Price of (KURA) Talks, People Listen - Stock Traders Daily
Kura Oncology to present AML trial data at ASH meeting - Investing.com
Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting - The Manila Times
Kura Oncology, Inc. Announces to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting - Marketscreener.com
Wedbush Reiterates Outperform Rating for Kura Oncology (NASDAQ:KURA) - MarketBeat
Kura Oncology (KURA) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Kura Oncology to Report Third Quarter 2024 Financial Results - The Manila Times
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors - StockTitan
UBS Group Initiates Coverage on Kura Oncology (NASDAQ:KURA) - Defense World
Kura Oncology (NASDAQ:KURA) Shares Gap UpHere's Why - MarketBeat
Kura Oncology's (KURA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Kura Oncology (NASDAQ:KURA) Receives New Coverage from Analysts at UBS Group - MarketBeat
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of - The Bakersfield Californian
Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST) - StockTitan
Kura Oncology Enters Oversold Territory (KURA) - Nasdaq
Lifesci Capital Upgrades Kura Oncology (NASDAQ:KURA) to "Strong-Buy" - MarketBeat
Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors - The Manila Times
Kura Oncology, Inc. (NASDAQ:KURA) Short Interest Down 5.2% in September - MarketBeat
Kura Oncology, Inc. (NASDAQ:KURA) Receives $29.20 Consensus Target Price from Analysts - MarketBeat
An analyst sees good growth prospects for Kura Oncology Inc (KURA) - SETE News
Where are the Opportunities in (KURA) - Stock Traders Daily
Kura downgraded to hold by Stifel, prefers rival Syndax - MSN
Kura Oncology (NASDAQ:KURA) Shares Gap DownHere's Why - MarketBeat
This Caterpillar Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
Kura Oncology (NASDAQ:KURA) Cut to "Hold" at Stifel Nicolaus - MarketBeat
Stifel sees challenges for Kura Oncology stock with delayed launch in AML market - Investing.com UK
Squarepoint Ops LLC Cuts Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Millennium Management LLC Sells 148,734 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Kura Oncology Inc (KURA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance
Investor’s Toolkit: Key Ratios for Assessing Kura Oncology Inc (KURA)’s Performance - The Dwinnex
Analyzing Kura Oncology Inc (KURA) After Recent Trading Activity - Knox Daily
Dimensional Fund Advisors LP Sells 468,816 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Examining Kura Oncology Inc (KURA) stock is warranted - US Post News
Kura Oncology Inc: Navigating Market Fluctuations with a 1.42B Market Cap - The InvestChronicle
Closing Figures Unveiled: Kura Oncology Inc (KURA) Drop -3.70, Closes at 18.50 - The Dwinnex
It is Poised to be a Bull Market for Kura Oncology Inc (KURA) - SETE News
Kura Oncology Inc [KURA] Stock sold by Insider Bair Teresa Brophy for $57916.0 - Knox Daily
Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by American Century Companies Inc. - MarketBeat
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology - The Manila Times
Kura Oncology's SWOT analysis: promising cancer drug stock faces pivotal year - Investing.com India
Armistice Capital LLC Has $48.39 Million Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Profund Advisors LLC Trims Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Affinity Asset Advisors LLC Reduces Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
Naval Daver, MDUnleashing the Innovation Era in AML: Practice Principles and Precision Medicine With Innovative Therapeutics - Audacy
Integral Health Asset Management LLC Takes $2.06 Million Position in Kura Oncology, Inc. (NASDAQ:KURA) - MarketBeat
The growth track for Kura Oncology Inc (KURA) has changed recently - SETE News
Integral Health Asset Management LLC Invests $2.06 Million in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
HighVista Strategies LLC Takes Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Rhumbline Advisers Reduces Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):